Nishmitha Puchakayala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nishmitha Puchakayala has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abhigyan Datta
Department of Neurology, University of Minnesota, Minneapolis, MN, USA
1 shared publication - Allimuthu Nithyanandam
Department of Neurology, Tamil Nadu Government Multi-Super Speciality Hospital, Omandurar Government Estate, Chennai, India
1 shared publication - Anmol Kaur
Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
1 shared publication Anusha Rai Deka
Gauhati Medical College and Hospital, Assam, India
1 shared publication- Arkansh Sharma
Government Medical College, Omandurar, Chennai, Tamil Nadu, India
1 shared publication Hardeep Singh Malhotra
Department of Neurology, King George's Medical University, Lucknow, Uttar Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 21 November 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis
Background: Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear. Objective: To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs). Methods: Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis. Results: Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects. Conclusions: Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.
- 21 November 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Open AccessPharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis
Background: Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear. Objective: To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs). Methods: Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis. Results: Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects. Conclusions: Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.